Design, synthesis and biological evaluation of 2,4‐diamino‐6‐methyl‐5‐substitutedpyrrolo[2,3‐d]pyrimidines as dihydrofolate reductase inhibitors

Nine novel nonclassical 2,4-diamino-6-methyl-5-mioarylsubstituted-7H-pyrrolo[2,3-d]pyrimidines 2-10 were synthesized as potential inhibitors of dihydrofolate reductase and as antitumor agents. The analogues contain various electron donating and electron withdrawing substituents on the phenylsulfanyl ring of the side chains and were synthesized from the key intermediate 2,6-diamino-6-methyl-7H-pyrrolo[2,3-d]-pyrimidine, 14. Compound 14, was in turn obtained by chlorination of 4-position of 2-amino-6-methylpyrrolo[2,3-d]pyrimidin-4(3H)-one, 16 followed by displacement with ammonia. Appropriately substituted phenyl thiols were appended to the 5-position of 14 via an oxidative addition reaction using iodine, ethanol and water. The compounds were evaluated against rat liver, rat-derived Pneumocystis, Mycobacterium avium and Toxoplasma gondii dihydrofolate reductase. The most potent and selective inhibitor, (2) has a 1-naphthyl side chain. In this series of compounds electron-withdrawing and bulky substituents in the side chain afford marginally active dihydrofolate reductase inhibitors. The single atom sulfur bridge in the side chain of these compounds is not conducive to potent dihydrofolate reductase inhibition.

[1]  W. W. Barrow,et al.  Identification and cloning of the Mycobacterium avium folA gene, required for dihydrofolate reductase activity. , 2006, FEMS microbiology letters.

[2]  R. Miller,et al.  Pneumocystis jirovecii infection , 2004, Thorax.

[3]  Xin Lin,et al.  Design, synthesis, and biological evaluation of 2,4-diamino-5-methyl-6-substituted-pyrrolo[2,3-d]pyrimidines as dihydrofolate reductase inhibitors. , 2004, Journal of medicinal chemistry.

[4]  M. Ihnat,et al.  Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases. , 2003, Bioorganic & medicinal chemistry.

[5]  I. Donkor,et al.  Synthesis and DHFR inhibitory activity of a series of 6-substituted-2,4-diaminothieno[2,3-d]pyrimidines. , 2003, European journal of medicinal chemistry.

[6]  F. Mavandadi,et al.  Synthesis of classical and a nonclassical 2-amino-4-oxo-6-methyl-5-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of thymidylate synthase. , 1999, Journal of medicinal chemistry.

[7]  V. Cody,et al.  Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines. , 1998, Journal of medicinal chemistry.

[8]  S. Queener New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. , 1995, Journal of medicinal chemistry.

[9]  P K Bryant,et al.  The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. , 1994, Structure.

[10]  J. J. Heusner,et al.  2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. , 1993, Journal of medicinal chemistry.

[11]  V. Georgiev Opportunistic/nosocomial infections. Treatment and developmental therapeutics. Toxoplasmosis , 1993 .

[12]  D. Roos Primary structure of the dihydrofolate reductase-thymidylate synthase gene from Toxoplasma gondii. , 1993, The Journal of biological chemistry.

[13]  H. Masur Prevention and treatment of pneumocystis pneumonia. , 1992, The New England journal of medicine.

[14]  J. Feinberg,et al.  New developments in the treatment of Pneumocystis carinii pneumonia. , 1992, Chest.

[15]  N Clumeck,et al.  Treatment of Toxoplasmic Encephalitis in Patients with AIDS , 1992, Annals of Internal Medicine.

[16]  M. Nettleman,et al.  Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. , 1991, JAMA.

[17]  J. Smith,et al.  Pneumocystis carinii, an opportunist in immunocompromised patients , 1991, Clinical Microbiology Reviews.

[18]  M. Nassiri,et al.  Synthesis, antiproliferative, and antiviral activity of certain 4-substituted and 4,5-disubstituted 7-[(1,3-dihydroxy-2-propoxy)methyl]pyrrolo[2,3-d]pyrimidines. , 1990, Journal of medicinal chemistry.

[19]  D. Stover,et al.  Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. , 1990, Annals of internal medicine.

[20]  J. Kovacs,et al.  Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. , 1989, The Journal of infectious diseases.

[21]  A. Rosowsky,et al.  2,4-Diaminothieno(2,3-d)pyrimidines as antifolates and antimalarials. 3. Synthesis of 5,6-disubstituted derivatives and related tetracyclic analogs. , 1973, Journal of medicinal chemistry.

[22]  F. Seela,et al.  7-Deazapurine Oligodeoxyribonucleotides: The effects of 7-deaza-8-methylguanine on dna structure and stability , 1998 .